Page 189 - Read Online

Page 18 of 20 Gim et al. Hepatoma Res 2023;9:51 https://dx.doi.org/10.20517/2394-5079.2023.90

Final results from FIGHT-202. Ann Oncol 2022;33:S379. DOI
43. Bekaii-Saab TS, Valle JW, Van Cutsem E, et al. FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced
cholangiocarcinoma with FGFR2 rearrangements. Future Oncol 2020;16:2385-99. DOI PubMed PMC
44. FDA grants accelerated approval to futibatinib for cholangiocarcinoma. Available from: https://www.fda.gov/drugs/resources-
information-approved-drugs/fda-grants-accelerated-approval-futibatinib-cholangiocarcinoma [Last accessed on 25 Dec 2023].
45. Goyal L, Meric-Bernstam F, Hollebecque A, et al; FOENIX-CCA2 Study Investigators. Futibatinib for FGFR2-rearranged
intrahepatic cholangiocarcinoma. N Engl J Med 2023;388:228-39. DOI
46. Goyal L, Meric-bernstam F, Hollebecque A, et al. Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in
intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements. JCO 2022;40:4009. DOI
47. Lau DK, Jenkins L, Weickhardt A. Mechanisms of acquired resistance to fibroblast growth factor receptor targeted therapy. Cancer
Drug Resist 2019;2:568-79. DOI PubMed PMC
48. Schaider H, Sturm R. The evolving universe of BRAF mutations in melanoma. Br J Dermatol 2017;177:893. DOI PubMed
49. Rose AAN. Encorafenib and binimetinib for the treatment of BRAF V600E/K-mutated melanoma. Drugs Today 2019;55:247-64.
DOI PubMed
50. Caputo F, Santini C, Bardasi C, et al. BRAF-mutated colorectal cancer: clinical and molecular insights. Int J Mol Sci 2019;20:5369.
DOI PubMed PMC
51. Ritterhouse LL, Barletta JA. BRAF V600E mutation-specific antibody: A review. Semin Diagn Pathol 2015;32:400-8. DOI PubMed
V600E
52. Subbiah V, Lassen U, Élez E, et al. Dabrafenib plus trametinib in patients with BRAF -mutated biliary tract cancer (ROAR): a
phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol 2020;21:1234-43. DOI
53. FDA grants accelerated approval to dabrafenib in combination with trametinib for unresectable or metastatic solid tumors with BRAF
V600E mutation. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-
dabrafenib-combination-trametinib-unresectable-or-metastatic-solid [Last accessed on 25 Dec 2023].
54. Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M. TP53 mutations in human cancers: functional selection and impact
on cancer prognosis and outcomes. Oncogene 2007;26:2157-65. DOI PubMed
55. Rizos H, Menzies AM, Pupo GM, et al. BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical
impact. Clin Cancer Res 2014;20:1965-77. DOI
56. Shi H, Hugo W, Kong X, et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov
2014;4:80-93. DOI PubMed PMC
57. Van Allen EM, Wagle N, Sucker A, et al; Dermatologic Cooperative Oncology Group of Germany (DeCOG). The genetic landscape
of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov 2014;4:94-109. DOI PubMed PMC
58. Shi H, Moriceau G, Kong X, et al. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired
B-RAF inhibitor resistance. Nat Commun 2012;3:724. DOI PubMed PMC
59. Wagle N, Emery C, Berger MF, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J
Clin Oncol 2011;29:3085-96. DOI PubMed PMC
60. Long GV, Fung C, Menzies AM, et al. Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy
of BRAF-mutant metastatic melanoma. Nat Commun 2014;5:5694. DOI PubMed
61. Wang B, Zhang W, Zhang G, et al. Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK
inhibition in BRAF-mutant melanoma. Oncogene 2021;40:5590-9. DOI PubMed PMC
62. Pópulo H, Lopes JM, Soares P. The mTOR signalling pathway in human cancer. Int J Mol Sci 2012;13:1886-918. DOI PubMed
PMC
63. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007;12:9-22. DOI PubMed
64. Iqbal N, Iqbal N. Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Mol
Biol Int 2014;2014:852748. DOI PubMed PMC
65. Ayasun R, Ozer M, Sahin I. The role of HER2 status in the biliary tract cancers. Cancers 2023;15:2628. DOI PubMed PMC
66. Galdy S, Lamarca A, McNamara MG, et al. HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis:
a potential therapeutic target? Cancer Metastasis Rev 2017;36:141-57. DOI PubMed PMC
67. Varga Z, Noske A, Ramach C, Padberg B, Moch H. Assessment of HER2 status in breast cancer: overall positivity rate and accuracy
by fluorescence in situ hybridization and immunohistochemistry in a single institution over 12 years: a quality control study. BMC
Cancer 2013;13:615. DOI PubMed PMC
68. Junttila TT, Akita RW, Parsons K, et al. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is
effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 2009;15:429-40. DOI
69. Javle M, Borad MJ, Azad NS, et al. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a
multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol 2021;22:1290-300. DOI
70. Tsurutani J, Iwata H, Krop I, et al. Targeting HER2 with trastuzumab deruxtecan: a dose-expansion, phase i study in multiple
advanced solid tumors. Cancer Discov 2020;10:688-701. DOI PubMed PMC
71. Vernieri C, Milano M, Brambilla M, et al. Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: current
knowledge, new research directions and therapeutic perspectives. Crit Rev Oncol Hematol 2019;139:53-66. DOI
72. Zhao D, Klempner SJ, Chao J. Progress and challenges in HER2-positive gastroesophageal adenocarcinoma. J Hematol Oncol
2019;12:50. DOI PubMed PMC